Premium
Increased serum procollagen III aminoterminal peptide in myelofibrosis
Author(s) -
Hochweiss S.,
Fruchtman S.,
Hahn E. G.,
Gilbert H.,
Donovan P. B.,
Johnson J.,
Goldberg J. D.,
Berk P. D.
Publication year - 1983
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830150405
Subject(s) - myelofibrosis , bone marrow , medicine , metaplasia , fibrosis , polycythemia vera , myeloid , radioimmunoassay , pathology
Myelofibrosis has been shown to involve an increase in type III collagen in the marrow. The aminoterminal procollagen III (PC III) peptide fragment is released during the production of PC III by fibroblasts and its serum level is therefore a marker for type III collagen synthesis. Using a recently developed sensitive radioimmunoassay, serum levels of PC III peptide were measured in 30 patients with myeloproliferative disease and 23 normal volunteers. Levels were found to be elevated above normal values in patients with polycythemia vera, even more elevated in patients with polycythemia and evidence of secondary myelofibrosis with mycloid metaplasia, and most strikingly elevated in patients with agnogenic myeloid metaplasia and severe marrow fibrosis. There was a significant association between serum levels of PC III peptide and the extent of reticulin fibrosis in bone marrow biopsies. Serum PC III level appears to be a quantitative marker for myelofibrosis.